Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 19 2026
0mins
Source: NASDAQ.COM
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ISRG with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 637.32 USD with a low forecast of 575.00 USD and a high forecast of 740.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 522.040
Low
575.00
Averages
637.32
High
740.00
Current: 522.040
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical's AI Surgical Robot Prospects
- Growing Market Demand: By the end of 2025, Intuitive Surgical has installed over 11,106 da Vinci surgical robots globally, marking a 12% increase from 2024, indicating strong demand in the healthcare sector for robotic-assisted surgeries.
- Increase in Surgeries: The number of surgeries performed using da Vinci robots rose by 18% year-over-year, reflecting not only the effectiveness of the technology but also hospitals' recognition of high-tech surgical solutions.
- FDA Approval of AI Enhancements: In late 2025, the FDA approved Intuitive Surgical's AI-based enhancements, which assist surgeons in making real-time decisions when a patient's lung shifts, thereby improving surgical safety and effectiveness.
- Future AI Surgery Potential: With an expanding database of surgeries, Intuitive Surgical has the potential to leverage AI for autonomous surgeries, providing world-class medical care, although its current price-to-earnings ratio of 66 may deter some investors while attracting aggressive growth seekers.
Continue Reading
Intuitive Surgical's da Vinci Robots See High Demand and AI Integration
- Growing Market Demand: By the end of 2025, Intuitive Surgical has installed over 11,106 da Vinci surgical robots globally, representing a 12% increase from 2024, indicating strong demand in the healthcare sector for robotic-assisted surgeries.
- Surgery Volume Increase: The number of surgeries performed using da Vinci robots rose by 18% year-over-year, reflecting not only the effectiveness of the technology but also the company's increasing market penetration in surgical procedures.
- AI Technology Integration: In 2025, the FDA approved Intuitive Surgical's AI-enhanced Ion endoluminal system, enabling surgeons to make real-time decisions in situations where a patient's lung has moved, marking the beginning of an AI revolution in robotic surgery.
- Significant Data Potential: With a vast database of surgical data, Intuitive Surgical may drive AI surgery advancements through data sales or partnerships with tech companies, potentially providing world-class medical care globally.
Continue Reading